Comparison of Triamterene-hydrochlorothiazide and Hydrochlorothiazide in refractory edema

The impact of Triamterene-Hydrochlorothiazide plus Furosemide versus Hydrochlorothiazide plus Furosemide in patients with heart failure and Refractory edema: A randomized clinical trial.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N37

Enrollment

Registered

2020-08-21

Start date

2019-10-21

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systolic and diastolic heart failure. Combined systolic (congestive) and diastolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: Will receive 25 mg Triamterene (in combination of Triamterene-H tablets product of Sobhan Pharmaceutical Company) daily plus standard treatment (Furosemide/Hydroch

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with systolic and diastolic heart failure and refractory edema GFR > 30

Exclusion criteria

Exclusion criteria: Renal dysfunctin (creatinine clearance of <30 ml/min) History of end-stage renal failure or dialysis Cardiogenic shock Acute myocardial infarction Hypoalbuminemia Any contraindications for Triamterene-Hydrochlorothiazide and Hydrochlorothiazide Patients who are not satisfied

Design outcomes

Primary

Measure	Time frame
Fluid Input/Output. Timepoint: Daily from admission day to discharge day. Method of measurement: Urine bag.;Measurement of Na and K. Timepoint: Daily from admission day to discharge day. Method of measurement: Laboratorial.;Edema. Timepoint: Daily from admission day to discharge day. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Entezari-maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3335 5983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026